Integral Diagnostics Limited
ASX: IDX
Capitol merger and premium mix fueled 34% revenue and 38% EBITDA growth.
(Source: TradingView) 3-Month Performance Profile of IDX on a DTF compared to S&P/ASX 200 (XJO).
Integral Diagnostics delivered a strong FY25 performance with revenue of $628.0 million, up 33.7% YoY, largely driven by the Capitol merger, which materially boosted revenue and EBITD
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
